Novel Therapeutic Approaches Targeting MDSC in Myelodysplastic Syndrome
Abstract
Myelodysplastic syndromes (MDS) is highly associated with both inflammation and aging. Our recent studies show that an inflammatory pathway, mediated by S100A9 and its receptor CD33, activates myeloid-derived suppressor cells (MDSC). These cells then kill the stem cells in the bone marrow and cause MDS. Thus development of drugs aimed at MDSCs may provide a unique opportunity to effectively treat MDS. Hence, the objective of this application is to test three novel therapeutic drugs that inhibit MDSC or stop their signaling. Two of the agents can block S100A9, or its binding to CD33 (S100A9-trap and anti-CD33 humanized antibody), while the last agent is our newly synthesized small compound, called ICT, which can downregulate the activation of MDSCs. These approaches provide highly effective targeted therapies for MDS. If successful, these strategies could have enormous clinical impact to benefit patients with MDS.
Document Details
- Document Type
- DoD Grant Award
- Publication Date
- Apr 04, 2016
- Source ID
- W81XWH1510440
Entities
People
- Sheng Wei
Organizations
- H. Lee Moffitt Cancer Center & Research Institute
- United States Army